RECEIVED
CENTRAL FAX CENTER
DEC 0 5 2006

IN THE CLAIMS

1. (currently amended) A compound of formula 1



(1)

wherein

A is nitrogen,

B is N-O,

R^1

(i) is $-C_{1-10}$-alkyl, straight-chain or branched-chain, optionally mono- or polysubstituted by –OH, -SH, $-NH_2$, $-NHC_{1-6}$-alkyl, $-N(C_{1-6}\text{-alkyl})_2$, $-NHC_{6-14}$-aryl, $-N(C_{6-14}\text{-aryl})_2$, $-N(C_{1-6}\text{-alkyl})(C_{6-14}\text{-aryl})$, $-NO_2$, -CN, -F, -Cl, -Br, -I, $-O-C_{1-6}$-alkyl, $-O-C_{6-14}$-aryl, $-S-C_{1-6}$-alkyl, $-S-C_{6-14}$-aryl, $-SO_3H$, $-SO_2C_{1-6}$-alkyl, $-SO_2C_{6-14}$-aryl, $-OSO_2C_{1-6}$-alkyl, $-OSO_2C_{6-14}$-aryl, -COOH, $-(CO)C_{1-5}$-alkyl, $-COO-C_{1-5}$-alkyl, $-O(CO)C_{1-5}$-alkyl, by mono-, bi- or tricyclic saturated or mono- or polyunsaturated carbocycles with 3-14 ring members or by a mono-, bi- or tricyclic saturated or mono- or polyunsaturated heterocycle with 5-15 ring members and 1-6 heteroatoms, ~~heteroatoms,~~

where the C_{6-14}-aryl groups and the carbocyclic and heterocyclic substituents in turn may optionally be substituted one or more times by at least one of $-C_{1-6}$-alkyl, -OH, $-NH_2$, $-NHC_{1-6}$-alkyl, $-N(C_{1-6}\text{-alkyl})_2$, $-NO_2$, -CN, -F, -Cl, -Br, -I, $-O-C_{1-6}$-alkyl, $-S-C_{1-6}$-alkyl, $-SO_3H$, $-SO_2C_{1-6}$-alkyl, $-OSO_2C_{1-6}$-alkyl, -COOH, $-(CO)C_{1-5}$-alkyl, $-COO-C_{1-5}$-alkyl or $-O(CO)C_{1-5}$-alkyl, and where the alkyl groups on the carbocyclic and heterocyclic substituents in turn may

optionally be substituted one or more times by –OH, -SH, -NH_2, -F, -Cl, -Br, -I, -SO_3H or –COOH, or

(ii)is –C_{2-10}-alkenyl, mono- or polyunsaturated, straight-chain or branched-chain, optionally mono- or polysubstituted by –OH, -SH, -NH_2, -NHC_{1-6}-alkyl, -$N(C_{1-6}$-alkyl$)_2$, -NHC_{6-14}-aryl, -$N(C_{6-14}$-aryl$)_2$, -$N(C_{1-6}$-alkyl$)(C_{6-14}$-aryl), -NO_2, -CN, -F, -Cl, -Br, -I, -O-C_{1-6}-alkyl, -O-C_{6-14}-aryl, -S-C_{1-6}-alkyl, -S-C_{6-14}-aryl, -SO_3H, -SO_2C_{1-6}-alkyl, -SO_2C_{6-14}-aryl, -OSO_2C_{1-6}-alkyl, -OSO_2C_{6-14}-aryl, -COOH, -(CO)C_{1-5}-alkyl, -COO-C_{1-5}-alkyl, -O(CO)C_{1-5}-alkyl, by mono-, bi- or tricyclic saturated or mono- or polyunsaturated carbocycles with 3-14 ring members or/and by mono-, bi- or tricyclic saturated or mono- or polyunsaturated heterocycles with 5-15 ring members and 1-6 heteroatoms,

where the C_{6-14}-aryl groups and the carbocyclic and heterocyclic substituents in turn may optionally be substituted one or more times by at least one of -C_{1-6}-alkyl, -OH, -NH_2, -NHC_{1-6}-alkyl, -$N(C_{1-6}$-alkyl$)_2$, -NO_2, -CN, -F, -Cl, -Br, -I, -O-C_{1-6}-alkyl, -S-C_{1-6}-alkyl, -SO_3H, -SO_2C_{1-6}-alkyl, -OSO_2C_{1-6}-alkyl, -COOH, -(CO)C_{1-5}-alkyl, -COO-C_{1-5}-alkyl or –O(CO)C_{1-5}-alkyl,

and where the alkyl groups on the carbocyclic and heterocylic substituents in turn may optionally be substituted one or more times by at least one of –OH, -SH, -NH_2, -F, -Cl, -Br, -I, -SO_3H or –COOH,

R^2 is hydrogen or –C_{1-3}-alkyl,

R^3 and R^4 may be identical or different and are hydrogen, -C_{1-6}-alkyl, -OH, -SH, -NH_2, -NHC_{1-6}-alkyl, -$N(C_{1-6}$-alkyl$)_2$, -NO_2, -CN, -SO_3H, -SO_3-C_{1-6}-alkyl, -COOH, -COO-C_{1-6}-alkyl, -O(CO)-C_{1-5}-alkyl, -F, -Cl, -Br, -I, -O-C_{1-6}-alkyl, -S-C_{1-6}-alkyl, -phenyl or –pyridyl, where the phenyl or pyridyl substituents in turn may optionally be substituted one or more times by at least one of -C_{1-3}-alkyl, -OH, -SH, -NH_2, -NHC_{1-3}-alkyl, -$N(C_{1-3}$-alkyl$)_2$, -NO_2, -CN, -SO_3H, -SO_3C_{1-3}-alkyl, -COOH, -$COOC_{1-3}$-alkyl, -F, -Cl, -Br, -I, -O-C_{1-3}-alkyl, -S-C_{1-3}-alkyl, or/and –O(CO)C_{1-3}-alkyl, and where the alkyl substituents in turn may optionally be substituted one or

more times by –OH, -SH, -NH_2, -F, -Cl, -Br, -I, -SO_3H, -SO_3C_{1-3}-alkyl, -COOH, -$COOC_{1-3}$-alkyl, -O-C_{1-3}-alkyl, -S-C_{1-3}-alkyl or/and –O(CO)-C_{1-3}-alkyl.

or a salt thereof ~~or salts of the compounds of formula 1~~.

2. (previously presented) A compound as claimed in claim 1 having at least one asymmetric carbon atom in the D form, the L form and D,L mixtures, and in the case of a plurality of asymmetric carbon atoms also the diastereomeric forms.

3. (canceled)

4. (previously presented) A compound as claimed in claim 1, wherein R^2 is -H or –CH_3.

5. (previously presented) A compound as claimed in claim 1, wherein at least one of R^3 and R^4 is a halogen atom.

6. (previously presented) A compound as claimed in claim 4, wherein R_2 is -CH_3.

7. (previously presented) A compound as claimed in claim 2, wherein R^2 is -H or –CH_3.

8. (currently amended) A compound as claimed in claim 7, wherein at least one of R^3 and R^4 ~~is i~~ is a halogen atom.

9. (previously presented) A compound as claimed in claim 1 selected from the group consisting of:

N-(3,5-dichloro-1-oxopyridin-4-yl)-[1-(4-fluorobenzyl)-7-azaindol-3-yl]glyoxylamide;

N-(3,5-dichloro-1-oxopyridin-4-yl)-[1-(2-fluorobenzyl)-7-azaindol-3-yl]glyoxylamide;

N-(3,5-dichloro-1-oxopyridin-4-yl)-[1-(3-nitrobenzyl)-7-azaindol-3-yl]glyoxylamide;

N-(3,5-dichloro-1-oxopyridin-4-yl)-[1-(2,6-difluorobenzyl)-7-azaindol-3-yl]glyoxylamide;

N-(3,5-dichloro-1-oxopyridin-4-yl)-[1-(2,4-dichlorobenzyl)-7-azaindol-3-yl]glyoxylamide;

N-(3,5-dichloro-1-oxopyridin-4-yl)-[1-(2-chlorobenzyl)-7-azaindol-3-yl]glyoxylamide;

N-(3,5-dichloro-1-oxopyridin-4-yl)-N-methyl-[1-(2-chlorobenzyl)-7-azaindol-3-yl]glyoxylamide;

N-methyl-N-(1-oxopyridin-4-yl)-[1-(2-chlorobenzyl)-7-azaindol-3-yl]glyoxylamide;

N-(3,5-dichloro-1-oxopyridin-4-yl)-[1-(2,6-dichlorobenzyl)-7-azaindol-3-yl]glyoxylamide;

N-(3,5-dichloro-1-oxopyridin-4-yl)-[1-(2-methylbenzyl)-7-azaindol-3-yl]glyoxylamide;

N-(3,5-dichloro-1-oxopyridin-4-yl)-[1-(2,6-dimethylbenzyl)-7-azaindol-3-yl]glyoxylamide;

N-(3,5-dichloro-1-oxopyridin-4-yl)-(1-hexyl-7-azaindol-3-yl)glyoxylamide;

N-(3,5-dichloro-1-oxopyridin-4-yl)-(1-isobutyl-7-azaindol-3-yl)glyoxylamide;

N-(3,5-dichloro-1-oxopyridin-4-yl)-(1-cyclopropylmethyl-7-azaindol-3-yl)glyoxylamide;

N-(3,5-dichloro-1-oxopyridin-4-yl)-[1-naphth-1-yl-methyl)-7-azaindol-3-yl]glyoxylamide;

N-(3,5-dichloro-1-oxopyridin-4-yl)-[1-(2-chloro-6-fluorobenzyl)-7-azaindol-3-yl]glyoxylamide;

N-(3,5-dichloro-1-oxopyridin-4-yl)-[1-(2-difluoromethylbenzyl)-7-azaindol-3-yl]glyoxylamide;

N-(3,5-dichloro-1-oxopyridin-4-yl)-[1-(2-cyanobenzyl)-7-azaindol-3-yl]glyoxylamide;

and physiologically tolerated salts thereof.

10-17 (canceled)

18. (previously presented) A drug product comprising a compound according to claim 1 and at least one of a conventional physiologically tolerated carrier, diluent or excipient.

19. (previously presented) A process for producing a drug product as claimed in claim 18, comprising admixing said compound with said carrier, diluent or excipient to form the drug product.

20. (previously presented) A pharmaceutical composition comprising a compound of claim 1 and at least one other active pharmaceutical agent.

21-26 (canceled)

27.(currently amended) The compound of claim 1, wherein the heteroatoms in ~~heteroatom is~~ (i) are N, O ~~N, 0~~ or S.

28.(currently amended) The compound of claim 1, wherein the heteroatoms ~~heteroatom~~ in (ii) are N, O ~~N, 0~~ or S.

29.(currently amended) The compound of claim 27, wherein the hereroatoms ~~heteroatom~~ in (ii) are N, O ~~N, 0~~ or S.